VolitionRx Publishes Peer-Reviewed Study Demonstrating High-Purity ctDNA Capture-Seq Technology

VolitionRx Limited (NYSE American: VNRX) has published the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company reports is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This advancement addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the vast background of healthy cell-free DNA. By creating highly enriched tumor DNA datasets, the technology holds promise for significantly improving cancer detection and monitoring.

The publication describes a two-step process that combines physical sample enrichment with bioinformatic filtering to produce sequencing datasets with greater than 99% purity of ctDNA. Early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings, according to the company.

VolitionRx estimates that the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications, totaling $36 billion. The company is currently conducting technical evaluations with potential licensing partners and is advancing larger validation studies with oncology key opinion leaders. It is also expanding patent protection for the technology as it explores commercialization opportunities.

The significance of this breakthrough lies in its potential to overcome a critical limitation in liquid biopsies. Traditional methods often struggle to detect the small fraction of ctDNA in blood, especially in early-stage cancers, leading to missed diagnoses. By enriching ctDNA to over 99% purity, Capture-Seq could enable more sensitive and specific detection, potentially allowing for earlier intervention and better patient outcomes. This could also enhance minimal residual disease monitoring, helping to detect recurrence earlier and guide treatment decisions.

Furthermore, the technology's ability to generate pure tumor DNA datasets may improve the accuracy of genomic profiling, leading to more personalized treatment approaches. As VolitionRx moves toward commercialization, the successful validation and adoption of this technology could have a profound impact on cancer care, potentially saving lives and improving quality of life for patients worldwide.

The peer-reviewed publication marks a significant milestone for VolitionRx, validating the scientific credibility of its approach. With ongoing studies and partnerships, the company is positioning itself to capitalize on the growing liquid biopsy market, which is projected to expand significantly in the coming years.